Cargando…

Interobserver Reproducibility of Diffusion-Weighted MRI in Monitoring Tumor Response to Neoadjuvant Therapy in Esophageal Cancer

OBJECTIVE: To investigate the reproducibility of diffusion-weighted magnetic resonance imaging (DW-MRI) in assessing tumor response early in the course of neoadjuvant chemoradiotherapy in patients with operable esophageal cancer. METHODS: Eleven male patients (mean age 54.8 years) with newly diagnos...

Descripción completa

Detalles Bibliográficos
Autores principales: Kwee, Robert M., Dik, Alexander K., Sosef, Meindert N., Berendsen, Ralph C. M., Sassen, Sander, Lammering, Guido, Clarijs, Ruud, Oostenbrug, Liekele E., Blom, Rachel L. G. M., Vliegen, Roy F. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3976260/
https://www.ncbi.nlm.nih.gov/pubmed/24704912
http://dx.doi.org/10.1371/journal.pone.0092211
Descripción
Sumario:OBJECTIVE: To investigate the reproducibility of diffusion-weighted magnetic resonance imaging (DW-MRI) in assessing tumor response early in the course of neoadjuvant chemoradiotherapy in patients with operable esophageal cancer. METHODS: Eleven male patients (mean age 54.8 years) with newly diagnosed esophageal cancer underwent DW-MRI before and 10 days after start of chemoradiotherapy. Reproducibility of apparent diffusion coefficient (ADC) measurements by manual (freehand) and semi-automated volumetric methods was assessed. RESULTS: Interobserver reproducibility for the assessment of mean tumor ADC by the manual measurement method was good, with an ICC of 0.69 (95% CI, 0.36 to 0.85; P = 0.001). Interobserver reproducibility for the assessment of mean tumor ADC by the semi-automated volumetric measurement method was very good, with an ICC of 0.96 (95% CI, 0.91 to 0.98; P<0.001). CONCLUSION: Semi-automated volumetric ADC measurements have higher reproducibility than manual ADC measurements in assessing tumor response to chemoradiotherapy in patients with esophageal adenocarcinoma.